OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>

BACKGROUND: There is no established treatment regimen for recurrent GBM. GBMs have activation of multiple signaling pathways in the tumor microenvironment, including the receptor tyrosine kinases, VEGFR, FGFR, and PDGFR. Regorafenib (REG), an oral multikinase inhibitor, inhibits these angiogenic kin...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Lombardi, G, de Salvo, G, Rudà, R, Franceschi, E, Eoli, M, Faedi, M, Pace, A, Lolli, I, Rizzato, S, Germano, D, Pasqualetti, F, Farina, M, Magni, G, Bellu, L, Caccese, M, Pambuku, A, Bergo, E, Indraccolo, S, Gardiman, M, Soffietti, R, Zagonel, V
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2018
Fag:
Oral Presentations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144013/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.016
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker